Atara Biotherapeutics, Inc. (ATRA) EPS Estimated At $

Elias Hubbard
April 17, 2018

Zero analysts have issued estimates for Atara Biotherapeutics' earnings. Following the sale, the chief executive officer now owns 348,978 shares of the company's stock, valued at $11,540,702.46. (NASDAQ:ATRA). Rhumbline Advisers reported 0% in Atara Biotherapeutics, Inc. It has outperformed by 77.18% the S&P500. Shares are trading price at $40.60 with move of -3.79%. Artal Grp invested in 0.27% or 1.00M shs. About 826,817 shares traded or 26.66% up from the average. William Blair reaffirmed a "buy" rating on shares of Atara Biotherapeutics in a research note on Friday, April 6th. (TSE:VRX) has 0.00% since April 13, 2017 and is. Its down 0.01, from 0.01 in 2017Q3. 12 West Cap Management Lp invested 0.87% in Atara Biotherapeutics, Inc. Amer Management Communication has invested 0% in ITT Inc. State Board Of Administration Of Florida Retirement reported 0% in Atara Biotherapeutics, Inc. The biotechnology company reported ($1.15) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($1.15). The insider Scalera Thomas M sold $458,637.

Among 2 analysts covering Opexa Therapeutics (NASDAQ:OPXA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 79% are positive. Atara Biotherapeutics had 27 analyst reports since September 9, 2015 according to SRatingsIntel. (NASDAQ:ATRA) on Wednesday, September 9 with "Buy" rating. In Tuesday, April 10 report J.P. Morgan initiated it with "Buy" rating and $5600 target. On Friday, October 28 the stock rating was downgraded by Chardan Capital Markets to "Neutral". Stifel Nicolaus maintained ITT Inc.

1/23/2018 - Atara Biotherapeutics was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating. The firm has "Hold" rating given on Tuesday, April 25 by Cantor Fitzgerald. The company was initiated on Tuesday, January 23 by UBS. On Wednesday, January 3 the company was upgraded by Citigroup. The company was maintained on Thursday, September 21 by Cantor Fitzgerald. The positive are 60%. After having $1.24 EPS previously, Valeant Pharmaceuticals International, Inc.'s analysts see -27.42% EPS growth.

Shares of Atara Biotherapeutics stock opened at $35.15 on Friday. (NASDAQ:ATRA) to report earnings on May, 3. Numis Securities has "Add" rating and GBX 50 target. 1,183 shares were sold by Gallagher Carol Giltner, worth $55,010. A sell rating on the other hand would be a recommendation to sell the security if now held, and avoid purchasing it on the open market. Canaccord Genuity initiated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have changed their positions in the stock by -20.02% over the past 6 months. The company was downgraded on Thursday, September 15 by Goldman Sachs.

Atara Biotherapeutics (ATRA) investors sentiment decreased to 1.42 in Q4 2017. 158,422 shares of the stock were exchanged, compared to its average volume of 1,084,020. The ratio dropped due to Atara Biotherapeutics, Inc. positioning: 9 sold and 17 reduced. 25 increased positions while 12 funds took positions. Schwab Charles Investment Management Inc. lifted its holdings in Atara Biotherapeutics by 20.8% during the fourth quarter. (NASDAQ:ATRA) for 61,978 shares. Jpmorgan Chase holds 0% of its capital in Atara Biotherapeutics, Inc. That's down 4.55 % from last year's $-0.88 earnings per share. Thompson Davis And owns 125 shares. (NASDAQ:ATRA). This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. Alps Advsr holds 33,904 shares. Also, the number of funds holding Atara Biotherapeutics in top ten equity positions was flat from 0 to 0 for the same number. Citigroup Inc accumulated 229 shares. Hudson Bay Capital Ltd Partnership stated it has 25,000 shares or 0.01% of all its holdings.

Atara Biotherapeutics, Inc. registered $14.24 million net activity with 0 buys and 20 selling transactions since October 11, 2017. (NASDAQ:ATRA) on Thursday, February 15. In the last ninety days, insiders sold 245,424 shares of company stock valued at $9,872,689. Zacks Investment Research's earnings per share averages are an average based on a survey of research firms that that provide coverage for Atara Biotherapeutics. On Monday, March 26 $729,265 worth of stock was sold by Haqq Christopher. Another trade for 6,000 shares valued at $242,460 was made by MCGRATH JOHN on Monday, March 19. BlackRock Inc. now owns 12,697 shares of the company's stock valued at $272,000 after buying an additional 6,597 shares in the last quarter.

Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for patients with severe and life-threatening diseases in the United States.The company has $1.75 billion market cap. Neuberger Berman Group LLC now owns 1,115,041 shares of the biotechnology company's stock valued at $18,454,000 after buying an additional 147,061 shares in the last quarter. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma. It now has negative earnings. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Click Lancashire

Discuss This Article